GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Passage Bio Inc (NAS:PASG) » Definitions » Price-to-Owner-Earnings

Passage Bio (Passage Bio) Price-to-Owner-Earnings : (As of Jun. 12, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Passage Bio Price-to-Owner-Earnings?

As of today (2024-06-12), Passage Bio's share price is $1.09. Passage Bio does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Passage Bio's Price-to-Owner-Earnings or its related term are showing as below:


PASG's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 34.445
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-06-12), Passage Bio's share price is $1.09. Passage Bio's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.53. Therefore, Passage Bio's PE Ratio for today is At Loss.

As of today (2024-06-12), Passage Bio's share price is $1.09. Passage Bio's EPS without NRI for the trailing twelve months (TTM) ended in was $-1.43. Therefore, Passage Bio's PE Ratio without NRI for today is At Loss.


Passage Bio Price-to-Owner-Earnings Historical Data

The historical data trend for Passage Bio's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Passage Bio Price-to-Owner-Earnings Chart

Passage Bio Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

Passage Bio Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Passage Bio's Price-to-Owner-Earnings

For the Biotechnology subindustry, Passage Bio's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Passage Bio's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Passage Bio's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Passage Bio's Price-to-Owner-Earnings falls into.



Passage Bio Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Passage Bio's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=1.09/-1.69
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Passage Bio  (NAS:PASG) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Passage Bio Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Passage Bio's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Passage Bio (Passage Bio) Business Description

Traded in Other Exchanges
N/A
Address
2005 Market Street, 39th Floor, One Commerce Square, Philadelphia, PA, USA, 19103
Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.
Executives
Kathleen Borthwick officer: SVP, Interim CFO C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Simona King officer: Chief Financial Officer C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Dolan Sondhi director C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Orbimed Advisors Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Alexandros Fotopoulos officer: Chief Technical Officer TWO COMMERCE SQUARE, 2001 MARKET STREET, 28TH FLOOR, PHILADELPHIA PA 19103
Sandip Kapadia director 450 WEST 15 STREET, SUITE 505, NEW YORK NY 10011
William Chou director, officer: Chief Executive Officer C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Monika Maria Toernsen officer: Chief Commercial Officer ONE COMMERCE SQUARE, 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Michael E. Kamarck director C/O UNILIFE CORPORATION, 250 CROSS FARM LANE, YORK PA 17406
Mark S Forman officer: Chief Medical Officer C/O PASSAGE BIO, INC., 2005 MARKET STREET, 39TH FLOOR, PHILADELPHIA PA 19103
Bruce A Goldsmith director, officer: CEO and President C/O PASSAGE BIO, INC., TWO COMMERCE SQ, 2001 MARKET ST, 28TH FL, PHILADELPHIA PA 19103
Orbimed Capital Gp Vii Llc 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Brian Burkavage officer: Controller C/O PASSAGE BIO, INC., ONE COMMERCE SQUARE, 39TH FLOOR, PHILADELPHIA PA 19103
Derrell Porter director C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD. #900, SOUTH SAN FRANCISCO CA 94080
Richard Steven Morris officer: Chief Financial Officer 397 EAGLEVIEW BOULEVARD, EXTON PA 19341